Treatment of @entity5736 and XXXX @entity1445 .

@entity1 @entity137 @entity2690 @entity5736 @entity2390 @entity1445 @entity413
UNASSIGNED: The most common @entity137 associated with @entity5736 and @entity2690 is hypoglycaemia. The article reviews existing evidence to better guide hypoglycaemia management. Sulfonylureas and @entity2690 have narrow therapeutic indices. Small doses can cause hypoglycaemia, which may be delayed and persistent. All @entity1 and adults with intentional @entity1445 need to be referred for medical assessment and treatment. Unintentional supratherapeutic ingestions can be initially managed at home but if symptomatic or if there is persistent hypoglycaemia require medical referral. @entity1 often require intensive care and prolonged observation periods. Blood @entity413 concentrations should be assessed frequently. Asymptomatic @entity1 with unintentional @entity5736 ingestions should be observed for 12  h, except if this would lead to discharge at night when they should be kept until the morning. Prophylactic intravenous @entity413 is not recommended. The goal of therapy is to restore and maintain euglycaemia for the duration of the drug's toxic effect. Enteral feeding is recommended in @entity1 who are alert and able to tolerate oral intake. Once @entity2690 or @entity5736 -induced hypoglycaemia has developed, it should be initially treated with an intravenous @entity413 bolus. Following this the mainstay of therapy for @entity2690 -induced hypoglycaemia is intravenous @entity413 infusion to maintain the blood @entity413 concentration between 5.5 and 11  mmol  l(-1) . After @entity5736 -induced hypoglycaemia is initially corrected with intravenous @entity413 , the main treatment is @entity2390 which is administered to prevent @entity2690 secretion and maintain euglycaemia. The observation period varies depending on drug, product formulation and dose. A general guideline is to observe for 12  h after discontinuation of intravenous @entity413 and, if applicable, @entity2390 .
